ABSTRACT
Objective We recently reported that hypertension (HTN) patients having at least three rounds of distinct treatment options (atl_three_roto) in a 12-month window have elevated risk of next-year complications. However, early identification of these “challenge to treat” patients is non-trivial and “drivers” of complications in these vs remaining HTN patients are not fully defined. To address these challenges/gaps, we present predictive models for preceding outcomes, delineate their “drivers”, and highlight value of their integration for population level risk stratification/management of HTN patients.
Materials and Methods 2.47 million HTN patients enrolled through 2015-2016 were selected from a nation-wide commercial claims database. Features associated with their treatment patterns, comedications, and comorbidities were extracted for 2015 and used to model/predict 2016 outcomes of atl_three_roto status and/or HTN complications. Logistic regression-derived odds-ratios were used to delineate drivers of each outcome.
Results Prior year treatment patterns, specific hypertension drugs (anti-hypertensives, calcium channel blockers, beta blockers), and congestive heart failure most increased future odds of atl_three_roto status. Regardless of prior year atl_three_roto status, specific comorbidities (renal disease, congestive heart failure, myocardial infarction, vascular disease, diabetes with chronic complications) and comedications (beta blockers, cardiac agents, anti-lipidemics) most increased future odds of HTN complications. Proof-of-concept analysis with an independent dataset demonstrated that integrating these model predictions/drivers thereof can be leveraged for risk stratification/management of HTN patients.
Discussion Integrating predictions and their “drivers” from above models supports early identification and targeted management of “at-risk” HTN patients.
Conclusion We have developed a predictive modeling based approach for risk stratification and management of HTN patients.
Competing Interest Statement
All authors are/were employees of Geneia LLC.
Funding Statement
No external funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Geneia Research Ethics Committee determined no ethics approval required
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵♦ Certain data used in this study were supplied by International Business Machines Corporation. Any analysis, interpretation, or conclusion based on these data is solely that of the authors and not International Business Machines Corporation.
Data Availability
The data used for this manuscript are commercially licensed from CCAE database and not publicly available.
